B. Braun is convinced that HES can be used effectively and safely in the authorized indications

0

B. Braun Melsungen AG stated today that medicinal products containing hydroxyethyl starch (HES) should be kept available for the treatment of patients” B. Braun (2018).

B. Braun report “B. Braun Melsungen AG stated today that medicinal products containing hydroxyethyl starch (HES) should be kept available for the treatment of patients. HES solutions are used as volume replacement solution in patients suffering acute blood loss due to a severe injury or surgical procedures when crystalloids alone are not considered sufficient. B. Braun is convinced that HES can be used effectively and safely in the authorized indications.

The Coordination Group for Mutual Recognition and Decentralised Procedures – human (CMDh), the committee in charge for the European Medicines Agency of the EU Commission, has recommended suspending the market authorization of HES in the EU through a majority vote. The final decision now lies with the EU Commission. The main reason for the CMDh vote was that HES products were frequently infused outside the authorized uses or despite contraindications for certain patient groups, e.g. in patients who are critically ill or those with sepsis.”

Full News Item

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.